ClinicalTrials.Veeva

Menu

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

Viatris logo

Viatris

Status and phase

Completed
Phase 3

Conditions

Pulmonary Hypertension

Treatments

Drug: Sildenafil citrate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00159861
A1481141

Details and patient eligibility

About

Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension

Enrollment

267 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with pulmonary arterial hypertension caused by primary PAH, associated with connective tissue disease or following surgical repair of a congenital heart lesion

Exclusion criteria

  • PH other than PAH

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

52

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems